Silicosis treatment

Alternative Silicosis Treatment Available at the Lung Institute

Traditional treatment for silicosis includes inhaled steroids and oxygen support, but these treatments typically only focus on the management of symptoms. While these options work for some people, others may experience negative side effects, such as an adverse reaction to a medication or a limitation on movement due to an oxygen machine. As an alternative treatment for silicosis, the Lung Institute offers cellular therapy. This groundbreaking therapy centers around the fact cells are derived from the patient’s own body. As a result, this alternative silicosis treatment is safe and comes with no risk of rejection.

The Lung Institute offers cellular therapy for the treatment of silicosis,  with the goal of reducing lung inflammation, improving lung function and slowing disease progression.

  • Blood-Derived Cellular Therapy

Both of these procedures are minimally invasive and are performed on an outpatient basis over the course of two days. Patients will be guided through every step of the treatment by our friendly and caring medical staff. Most patients are able to immediately return to daily activities after their procedure, and many report an improvement in their overall quality of life as a result of the therapy.

To learn more about the cellular therapy we offer as an alternative treatment for silicosis, as well as options for prevention, call the Lung Institute today at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.